Q4 2019 Earnings Call
Good day and welcome to the Heska Corporation fourth quarter and full year 2019 earnings call. Today's conference is being recorded at this time I'd like to turn the conference over to Mr., John Eckart Director of Investor Relations. Please go ahead Sir.
Thank you and good morning, everyone. Welcome to ask a corporation earnings call for the fourth quarter in full year of 20 Nike.
Tony Gardy director of Investor Relations for Heska.
Prior to discussing Heskas fourth quarter and full year 20, Nike results I would like to remind you that during the course of this call we need to make certain forward looking statements regarding future events or future financial performance of the company you need to caution you that any such forward looking statements are based on our current beliefs expectations and involve known and.
Known risks and uncertainties, which may cause actual results and performance to be materially different from that expressed or implied by those forward looking statement.
Factors that could cause or contribute to such differences are detailed in writing in this morning's earning release Heska Corporation annual and quarterly filings with the FCC and elsewhere.
Any forward looking statements speak only as of the time there maybe that's good did not understand and specifically disclaims any obligation or in kunshan to upbeat any forward looking statements to reflect design that occur after the times I've seen that was made.
We have what does this morning, Kevin Wilson, Heskas, Chief Executive Officer in precedent.
Catherine Gretchen Haskins, Chief Financial Officer, Mr. Wilson, and that's craftsmen will provide details surrounding the results reported and then we'll open the call. The question at this time that it's my pleasure to turn the call over to Kevin Wilson, that's good CEO and President Kevin.
Hey, Thanks, John Good morning, everybody.
Today, we are pleased to report great fourth quarter, and a strong full year performance it met and exceeded carriers or 2019 outlook that we presented this time last year.
The details of these results are provided in this mornings release.
For those of you who have followed asking for some time you. All know we work inside your plans, but first of which was from 2013 2018.
June 2020 will be exactly halfway through our cost five year plan.
As we approach this milestone I'm encouraged that during this first capital of five year plan, we're on target to achieve all three rails have announced initiatives.
First major growth initiative is to double the addressable customers and geography, which we sure.
With the groundwork late in 2019 in 2018, as we began 2020 I'm proud that we've now built acquired or obtained the right to acquire business geography in markets that more than double haskins reach and addressable customers.
Beginning in 2020, Haskell, how longer reach and broader geographic diversity the money in all historical pure set of companies.
We are thrilled with our advancements in the international fraud.
Yeah, patiently and efficiently deploying capital to build or acquire scarce crucial unique an extraordinarily difficult to replicate geographic assets.
From these assets, we see significant sales growth gross margin integration opportunities to deliver broad geographic reach economic diversification size scalability and substantial value to customers and large industry partners.
We will integrate optimize and begin to grow these international markets, namely in core Europe, Australia, and Canada over the balance of 2020 to create substantial value for all stakeholders.
Our second major growth initiative is double the addressable product revenue lines, we serve again, what the groundwork late in 2018 in 2019 as we enter 2020, we now look door element RC rotor chemistry platform for international markets, our new element I plus immuno assay line for all.
Global markets and our anticipated success and the final stages of development at early stages of launching of our new element you up your entry equal imaging analyzer line, which wasn't till recently attended initially only for domestic markets and 2020 and 2021 and is now targeted for global markets out law.
Josh.
I believe firmly and without doubt that Heska now has one of the best innovation pipelines and all of them while diagnostics.
An achievement I believe that will deliver strong value for all stakeholders in the second half of our five year plan and beyond.
Our third major growth initiative is to continue to grow when our existing lines and geography is a business by building upon the past six years of consecutive market share gains in our core diagnostics product lines.
2019, Heska teams accomplish that goal Auxel and delivered solid results in our core existing wise in locations.
What we said we wouldn't do and in key areas, we didnt, even more with our core point of care loud diagnostics exceeding expectations in nearly every way or customer base. After me utilization and improved mix at high volume users grew in 2019, which drove a historic annual growth rate of night.
18.7% in Haskins key point of care lab consumables business line.
Which is our largest revenue highest margin and fastest growing core line. It was a rock solid performance.
This 19.7% growth beat our outlook for 12% to 17% growth.
Overall subscription retention was in line at 95% growth.
Gross margins grew.
And as detailed in this mornings release, our recently expanded sales teams delivered significantly better than expected annual growth in months under subscription minimum contract subscription value and monthly contracts subscription value.
We expect the direction of these positive trends to continue in 2020 and beyond.
For those new to Heska, we indicated at the beginning of 2019 that softness in our non core legacy try hard part one preventative, which we contract manufacturer for third party would offset these successes in 2019, I roughly $15 million compared the prior year. This was the case.
Also as announced we see some of these sales beginning to returning 2020, which we will detail later on the call.
In two years Heska teams have doubled our global reach advanced our proprietary innovation pipeline to the level of substantial competitive advantage.
Gained market share in our existing core diagnostics businesses invested heavily in infrastructure on commercial team expansion.
Adding key leadership experts to the team.
Expanded and improved our balance sheet, which is in excellent condition and generated positive operating cash.
We have made your company far more valuable.
After to focus years of preparation and investment in the first half of our five year plan.
We now anticipate that our major initiatives will begin to drive economic performance by the end of 2020 with strong acceleration in the second half of our five year plan.
This is consistent with our performance in our first five year plan and we are comfortable with our next steps and how to take them.
With these milestones clearly insight I.
I would like to extend my most sincere and respectful thanks to each member of our Heska teams that have made this next phase possible.
Together in a short time may have transformed Heska and 20 global company with proprietary and exclusive technologies broad reach and capabilities and above market growth potential.
Due to their hard work has concept to capitalize on the best period of opportunity for diagnostics company.
I can recall in my nearly three decades, and the animal health space.
Fully aware of the challenges in front of us on the strength and size of our competitors I continue to expect our success because of our people.
The size of our opportunity relative to our own size or plan are healthy and consolidated global pet animal health care markets and our unique position within these markets and with our customers in a world War diagnostics represents 35% of the sales and profit something that's from veterinary hospitals.
Which are themselves growing unhealthy, we think heskas unique close and scarce physician closest to the veterinarians and pet families is very valuable.
In the coming two and a half years, we intend to demonstrate quietly that value.
With that I'll turn the call over to John to walk through our product development schedules with other updates outlined in this mornings release Scott.
Thank you Kevin and thank you again, everyone for joining us this morning.
We presented a lot of good information in today's release and we want to take a moment to call out some of the high points before Catherine covers the financial details.
First I'd like to take a moment to overview our progress in product innovation.
That's good continues to focus on growing its highest quality revenues by innovating to solve big and meaningful problems for customers and that families.
Solving these problems uniquely and better than the competition put Tesco closest to the veterinarian and by extension.
Hamleys.
We believe Heskas research and development activities are squarely on target the self critical pet health care challenges by developing diagnostics products that meet a majority of the following attributes.
First they solve for big problems and challenges.
Second the our proprietary exclusive developed manufactured and sold by Heska.
Third they reach far out on the innovation and value add curve to leap frog and obsolete the competition and fourth they are offered globally through has a direct and indirect channels.
For 2018 has get invested $4.9 million more in research and development than the prior year and 3 million more in sales and marketing to expand the domestic sales team and international large group in anticipation of new products from our innovation pipeline.
While smaller than the competition teams and budgets, we strongly believe in the talent and targeted focus of Heskas teams and development areas [noise].
In June of 2018, we introduced progesterone and be went to Heskas immuno assay and blood gas analyzers respectfully.
That's all that's giving you Kinda Street, you wrap plus panel.
These product watches helped deliver strong retention increased utilization in 2019.
We see menu expansions like these two existing platforms continuing to contribute and its similar way in 2020 and beyond.
Specific to Heska analyzer platforms Heska introduced to the element RC rotor chemistry targeted to international markets in June of 2019 in advance of our anticipated Barger geographic expansion.
Initial sales of element RC commenced in the third quarter of 2019 early reception has been favorable.
With the acquisition integration and growth of our international markets now in full swing in early 2020 full element RC really is now quickly ramping monthly to coincide with this geographic expansion.
Element RC is firmly tied to international and Heska is now because the races internationally.
Also in 2019 Heska began early limited release of Heskas, New element I plus our next generation immuno assay platform for global veterinary and animal health applications.
And I quite significantly advances Heska is currently being amino assay platform with multiplexing test cartridge is superior analyzer design.
Lower cost.
Expansive roadmap and global market exclusivity within Heskas full point of care line.
Early reception and feedback has been favorable.
Full market release and menu availability is now quickly ramping monthly an element I plus is now expected to be broadly available in North America in Europe, and the second quarter of 2020.
And lastly, we moved to element U.S. heskas highly anticipated yearning FICO solution.
Element you Apis Heskas artificial intelligence enabled yearning fiegel imaging analyzer platform for global Veterinary animal health application.
Element you ask is expected to be a major first mover innovation from Heska that Phelps big unimportant problems for veterinarians and a point of care market estimated to be $400 million.
In North America and of similar size outside of North.
Let's go began prelaunch viewing element you epic that the MX conference in Orlando in January and W. E Com Las Vegas in February.
Spot man has been favorable resulting in over 50 customer commit competitive customer site and current heska reset subscribers that has committed to element U.S. along with it.
And increases to their existing Heska lab subscription.
That's good continues to believe now more firmly than ever and the demand and opportunity for element you out.
That's good element you up searching development investments to date has continued to yield on target and on time results.
After element you have instrument to enhance to begin verification validation and optimization of beta instruments for final sign off before full production is authorized.
You are patch for many quarters being scheduled for beta pre releasing a third quarter of 2020. This milestone has now moved to the fourth quarter due to three factors.
First.
That's good substantially acquisition in Europe TESSCO is preparing for initial launch in North America and now also in European markets with adjustments in manufacturing volume supply chain and logistics support network in logistics in manufacturing and use your safety requirements for core European markets, Canada.
And Australia.
Second.
Location of supply chain and manufacturing at final commercially available element you up analyzers is being evaluated.
Currently evaluating updated plans to manufacture these analyzers in the United States.
We do not anticipate major disruption in supply chain components.
Next week affected by health epidemics allowances for delays are being incorporated into this updated element you have schedule.
And third.
Allowance for further optimization of alpha to beta design simply but we will use the time it from the above schedule allowances to further optimize engaging or data sets and advancing beta units delivery channel commercially lease in quantity.
Now I'd like to take a few quick moments to overview, our very rapid progress in expanding haskins addressable geographic markets.
That's been 2019 acquisition of optimizing France is now complete and it is making good progress.
[noise] teams are trained any point of care lapses subscription get installed and continuing in France.
Also performing well test Australia.
Which continues to run slightly ahead of expectation when they went and point of care that diagnostic Sip secured a foothold on which the team has continued to build it and the learnings from our work in Australia has provided a detailed roadmaps for future Heska expansion.
Moving to the key market of Spain on January nine Twentytwenty Heska announced it funded its acquisition of Cbm companies.
BBM companies had been leading providers for over 25 years. It ended union blood testing products to the companion animal market in Spain.
Market with approximately 6000 veterinary clinics and hospitals.
Dan is successful and unique Cbm company guesstimate their market share prior to joining Heska <unk> number one in ultrasound.
Number one in digital radiography and number two and point of care blood diagnostics.
The integration of Cbm companies, while still early is progressing well an initial indications point towards favorable long term opportunity for heska in Spain and broader Europe.
Moving onto a greater Europe, and the surrounding markets, including Germany, France, Italy, Spain, Scandinavia and eastern Europe.
On January 14th Twentytwenty Heska entered into an agreement to acquire 100% like the capital stack of skill animal care company simply Vectrus.
Founded in 1998 in had putting in Germany with facilities and operations also in France, Italy, Spain, and Canada skill has grown into of veterinary point of care laboratory in imaging diagnostics leader.
Having pets and their families across Europe and the global.
By combining skill in the recently announced that Scott two of the world's top veterinary diagnostics companies will come together to service millions of pets to tens of thousands of veterinarians in active analyzers in over 25 countries.
With an expectation to win at top three market share position in key markets.
With these combinations, we target market share of 13% in the United States in Canada, 40% in Germany, 40% in Spain.
8% in France.
18% in Italy, and meaningful growth elsewhere.
Together they knew had Scott will be powered by over 500 employees dedicated to diagnostics sales teams in 10 countries spanning Europe Latin America in Australia.
We anticipate generating approximately 200 million and sales for 2020 subject to the closing date and other factors.
We expect to drag approximately 93% have our sales from our core companion animal focus that total 2020 sales estimated to come from a strong synergistic mix of approximately 60% laboratory and 23% imaging.
Approximately 10% coming some high their core companion animal products and 7% from other vaccines in pharmaceuticals.
And you expect to benefit from a favorable mix and geography, it's 67% of sales from North America, and 33% from our international markets.
Approximately 92% of these sales.
We'll be occurring in our core companion animal segment.
This is the Miss the mix that Heska has been seeking now for some time.
The skill acquisition remains on track to close in the second quarter of 2020 targeted for April 1st subject to customary closing conditions.
Until that time.
While we are excited to share more information with customers the investors Intel we own the assets, which are currently held by another publicly traded company. We are unable to share nonpublic information and other information.
Lastly, we turned to corporate accounts, which continued to perform well for Heska. It's a number of sites continue to grow and we continue to see major chances to expand and extend our relationships with groups in North America, and now with our new international capabilities in Europe, Scandinavia and elsewhere.
[noise], having covered a lot of information, though I will now turn the call over the Catherine to go through the details of the quota and if the full year catching thanks, John and good morning, everyone. Rare claims reported strong customer for the fourth quarter 2019, [laughter] full year, 2019, which were inline with our overall expectations communicated.
This time last year.
As we begin I'd like to point out, but I'll be discussing our results as reported on a GAAP basis as well as on an adjusted non-GAAP basis.
Fourth quarter and full year for both 2019 and 2018 non-GAAP results.
Certain adjustments that are detailed in a reconciliation of GAAP to non-GAAP schedule included with the form 8-K furnished with the FCC evolved in the press release.
Consolidated revenue for the fourth quarter was 33.8 million eight 0.9% decrease over the fourth quarter 2018 full year 2019 revenue was 122.7 million a 3.8% decrease over full year 2018. The topline result was generally in line with our 29.
We reported she's segment's core companion animal or see theory, and other vaccines and pharmaceuticals or ODP.
Revenue in RCC segment was 30.8 million I Wonder, if 2019, and 8.9% increase over the fourth quarter kind of 18 revenue for the full year 19 decreased 2.2%.
100.
All I can start to the full you're confident pool.
And there are some point of care laboratory consumables grew 20 now I'm sorry in the fourth quarter 20, now cool compared to the fourth quarter from April at school year consumables revenue grew like 1.7% 53.6 million exceeding our full year outlook of 12% to 17% strong customer utilization, we test offerings.
Doctors attributing [noise].
Revenue from anything related instruments grew 36.8% to 9.79 in the fourth quarter 29, cool as compared to the fourth quarter 28 pool.
Well, you're 29 to 11 isn't imaging related instruments grew 12.4% to 25.7 level as compared with a full you're currently.
Imaging revenue was just short of our 20 nicely outlook due primarily to lower sales filled international.
Revenue from Oh, VP segment decreased 48.7% to approximately 3 million in a fourth quarter pretty notable as compared to the fourth quarter of 28 pool for the full year 2019 revenue in our OLTP segment declined 13.1% to 16.19 I compared to the full year.
Oh VP segment results results fell short of our pull your guidance to the supply issues of certain raw materials.
Consolidated gross margin in the fourth quarter 29, close to 46.9%, that's compared to 45.4% and a fourth quarter 28.
Consolidated gross margin for the full year of 20 to 40.
<unk> was 21 and inline with school your expectations.
And the fourth quarter 20, multiple gross margin in RCC segment grew over 400 basis points to 51% or compared to the fourth quarter total tool.
Good day margins for the full year 20, <unk> increased 200 basis points at 50.3% as compared to full year total Colom go your claim licenses gross margin with Evercore 29 outlook due to higher level of consumable. Furthermore.
Well the piece segment margin decreased approximately 3400 basis points to 4.6% in the fourth quarter of 29 cool as compared to the fourth quarter 20 equal.
And full year 2019 gross margin decreased approximately 700 basis points.
As compared to full year, two will only be 2019 gross margin was unfavorable as compared to our 2019 outlook due to increased quite utilization charges as a result of the raw material issue.
The place you I referenced earlier.
Operating income in the fourth quarter, pointing out to decreased to 775000 or starting to 6.6% as compared to the fourth quarter of 28.
The full year 29, cool operating income decreased 91.4% to 327000 as compared to full year 20 equal.
Non-GAAP operating income in the fourth quarter decreased 1.4 million or 59.1% as compared to the fourth quarter kind of equal.
Full year non-GAAP operating income plain loan pool was 1 million decrease of 91.1% our compared to non-GAAP operating income for 22 for both metrics in all periods presented the decline was primarily due to <unk> to purposeful investment in research and development for innovative products as well as international expansion of sales and marketing.
Previously discussed on this call.
Both GAAP and non-GAAP metrics, we were in line with our previously tool kit a 29 <unk> outlook for both operating income and operating margin.
Adjusted EBITDA for the fourth quarter of 20, multiple decreased 37.9% to 3.8 million as compared to the fourth quarter putting into.
Full year 2019, adjusted EBITDA decreased 50.6% to 10.4 million as compared to the full year 22 decreases and both periods were consistent with decreases it's unclear operation.
For full year 29, cool and 22, we generate a tax benefit of 1.4 million a 2.1 million respectively. The tax benefit is driven largely by discrete tax benefits associated with stock compensation.
Net loss attributable to Heska for the fourth quarter of 29 tool with approximately 1.7 million or a loss of 23 cents per share compared to income of 3.5 million or earnings of 44 cents per diluted share in the fourth quarter total net loss attributable to have stuff for the full year twin lakes and it was one point.
Five level or a lot 20 cents per share.
Compared to income of 5.6 million or earnings of 74 cents per diluted share for the full year 28.
In addition to lower operating income net loss attributable to Heska with further burdened by both the cash coupon and non cash amortization related to the convertible debt issuance in September kind of like school.
On an adjusted basis non-GAAP net income per diluted share for the fourth quarter of 20 local was seven cents as compared to 54 cents in the fourth quarter kind of April.
Full year 2019, non-GAAP net income per diluted share was 37 cents as compared to $1.64 cents per diluted share totally tool.
As of December 31st Twain, All told we had approximately 89 million on cash compared to 13.4 million as of December 31st 22.
Significant increase in pass as a result restaurants are the 86.25 million aggregate principal amount, 3.75% convertible senior notes due 2020.
In early January 2020, Heska completed its funding of approximately 14 million or the acquisition of the CV I'm comfortable discussed earlier on this call.
Our recently announced acquisition ASCO will be financed through a private placement of preferred equity, which is convertible upon the authorization of additional common shares.
Cash flow from operations provided 3.3 million and 29.
Regarding the outlook for 2020, our guidance includes only Heska Corporation as it stands today February 20 to 2021, we did not include the potential impact of acquisition skill or the chart transaction have not yet quote.
The sensitivity around providing information relating to a subsidiary of another public that's to perhaps prohibits us from sharing information prior to close within a reasonable amount of time at the close of the transaction likely to coincide with our first quarter earnings call, providing the transaction closes on or around April 1st we will provide an update of too.
20 outlook, because we anticipate significant variation in our operating result, as a result, and still acquisition as well other transactions such as the convertible debt issuance, we're going to provide guidance on historical results adjusted for certain items, but we believe a mobile our investors or analysts to better understand the underlying.
<unk> operating performance of our business.
We're 2020, well to suppose topline consolidated revenue to be between 135 million and 145 million with CCH segment revenue of 120 million to 130 million, which is primarily driven by a projected 12% to 17% growth in consumable revenue.
We anticipate a modest impact the point of care laboratory revenue pretty young people analyzer launch anticipated for the fourth quarter imaging related revenue is projected to be in a 25 millimeter 30 million range.
Could it or CCB revenue projection is approximately 4.5 million of revenue related to try hard.
[noise] 2020, Ob PT revenue is projected to be nearly in line with 29 cool, but we will experience variability throughout the year based on timing production compared to 22.
Adjusted EBITDA margin for 29 cool was approximately 8.5%.
We have guided adjusted to tighten the range of 6% to 8% for 2020, but we expected to be closer to the high end of the rules.
Selling general and administrative indefinitely, <unk> will increase to support new product launches international expansion efforts and to support other strategic initiatives research and development costs are expected to be inline with total tool, but skewed to the going on 2020.
With regard to non operating items, we will incur approximately 3 million no cash interest associated with our convertible debt.
Amortize, an approximate 6 million relating to the debt discount and issuance costs.
We experienced significant volatility in our overall effective tax rate due to the there are two discrete tax benefits from stock based compensation activity intact, but from executive compensation limitation.
Not including the impact of tax items, we estimate a benefit of 15% to 20%.
Based on historical tax items, the benefit could increase up to 40%.
We do not expect to generate cash flow from operations and 2020 as a result of investment in inventory in anticipation of the Newpark launch a bigger equal as well as the cash interest associated with our convertible debt.
That concludes our financial review, but that we would like we would like to open up a call for questions operator.
Absolutely she'd like to ask a question. Please take note by pressing star one on your telephone keypad you aren't using a speakerphone. Please make sure. Your mute function is turned off to a lot of your signals to reach or equipment.
Once again press Star one Sascar question.
For school with venture Cooper from Raymond James. Please go ahead.
Alright, Thanks for the question I guess.
First and maybe Youre.
And maybe I will tell me to wait until after the deal close, but as we think about scale and sort of the the moving parts of what you're acquiring in the 200 million kind of target that has left the same as it was initially how do we think about component to that business and.
We see the pieces you now you relative to some amount of a business that is distributing a competitor products and things like that how do we think about <unk>.
As well as with the you know the conversion to subscription or how are we thinking about that business on a on a go forward relative to the information that is already out there from go veteran of roughly 80 million of revenue for them last year.
Yes, So Ah Hey, Andrew it's Kevin.
You know the details we can't get into until it closes, but but having said that.
There are a couple of things and.
I would point out the first since you when you annualize that based on ownership of April 1st.
I think obviously, there's not a full year of ownership so that substantially reduces.
Baseline.
The second is we do anticipate revenue recognition changes as we as we go to.
Christian model, which dampens the heat pump equipment recognition.
I would think against long term economics and pricing gross margin all the things are we just deliver.
And our U.S. marcon front for for the corner on here. So I think those two things largely.
Justify the Oh the guide.
Consolidated 200.
We will have more detailed information.
In addition to what we think.
Gross margins are some of those types of things.
When we bought validated almost like one next call.
I'm certainly close all around April 1st style, which we think will.
Okay. That's helpful and then on kind of the core guidance.
Look at how.
The consumables number was relative to our expectation in Fourq you you know I thinking in that context 12 to 17 is actually maybe a little bit less than we would've hoped after 30% is there anything in either for Q that pump that number a little bit higher that's not going to repeat or anything along those lines as to why when we look at.
The comps in first half 2020, and moving through the year.
We're kind of at that 12 to 17 as opposed to something a little bit higher given me a subscription model what would make us think that there would be more flow through from the fourth quarter Pete.
So and I like Katherine jump in if I Miss anything big but the big one is.
Just delivered to a well above comp comp.
So you you lap that.
Close.
I can prudence would say.
Keep the guidance.
12 to 17, I think it's a prudent guidance.
Okay. So would you I guess kind of on that would you say if you look if I answer your question directly nothing in the fourth quarter was a onetime impact I think thats. What you were asking right. If we compare to what we believed what was a.
Quarter from 2018.
Right.
What we had expected.
Okay, and then I guess would that.
You know would it be safe to assume then that Fourq you relative to the monthly minimum you where you know further above then kind of your average quarter is that fair way to characterize it.
I would say utilization was strong in the fourth quarter.
But I I play I I hesitate to look at things only quarterly.
Annual Ah weight was more reflective of.
The average increasing utilization across the board.
Okay. That's helpful and then I guess.
Lastly, I know, it's growing a smaller and smaller pieces of business, but when we think about over U P. And you know what it always been kind of talk to you as a you know in inflationary type grower I think you missed the number a little bit and in 2019 and are a little bit lower than we expected in 2020 is that a business that you know we should think of as.
Being stabilized around the range that you guided in 2020 or.
Any context, you can provide there and on on gross margin and then also you know I know you talked about in the press release. Some are the manufacturing that that you can do potentially in those facilities, but from a strategic perspective sort of what that piece means and how you view it as a business has continued to trend downward a little bit.
Yes, I'll, let Catherine jump in as Walt and that's something but but that that business has declined her for many years. It's a it's a contract manufacturing vaccines in pharmaceuticals focus.
Uh huh.
That said, we do have activities and that plant that positively impact our core companion animal segment.
Try hard for instance comes out of that facility in last year not a lot of try our came out a at all due to what we had anticipated and announced and so I think some of that will return, but that's probably utilization.
And all kinds of other things that flow through that so.
I think it's stabilizing at that at that level, we feel we feel good about the guide.
For 2020, you know, we don't expect big.
Big swings in that it does have a fairly.
Clear forecasting abilities a lot of these things are long lead time and a lot of these are contract minimums.
With the contract manufacturing agreements that we have show.
I I do like the mix it were that were hitting now the vaccines pharmaceuticals.
Under 10% at roughly 7% on a go forward basis, and 2020 interim factor in the acquisitions.
And I think I think that's a positive direction re utilizing some of that capacity in des Moines.
I'm sure regulated cast cartridges friendships, we got a lot of art tests will require U.S. FDA ft. Any those types of things in that and that facility has have types are scarce resource and we happened on one. So we do think we'll get long term value out of that.
Okay, great I'll leave it at that thanks.
Okay.
Thank you well next take Jim Sidoti. Please go ahead Sir.
Good morning question on R&D, you made a comment in the press release.
Strict already to stay about the same level.
Revenue in 2020 years was in 2019 sort of be clear that's.
Prior to the acquisition of skill.
Right correct.
Okay occurs.
I know you don't want to get a good detail, but I.
I would think the skill business does not require the same level R&D as a core business. There was no fair statement.
We think that's fair, we think our R&D.
Combined with what they've done in the past.
We don't we don't think you have to duplicate the effort. So there there's definitely some synergy there we're coming out with a crazy good pipeline and the scale folks have a fantastic go to market team.
But I don't think when you can duplicate our R&D spend over his skill.
Okay, and then second works for me goodwill and other intangibles it went up to around 36 million.
If you ended the year from about 27 million.
And that's on prior to the closing of these two deals was there. Another deal are there that I missed.
As seen in CV I'm actually all this consolidated in the beginning of December.
Okay, all right that's it thank you.
Yes.
[noise]. Thanks for question once again I'd like to remind everyone that if you'd like to ask a question. Please signaled by pressing star one on your telephone keypad.
It appears that we have no more questions in queue. At this time I'd like to turn the conference back over to Mr., Kevin Wilson. Thank you.
We must have done a great job of answer and everybody's questions what that really long script.
Thank you everybody for joining our call. We really appreciate the time I know, it's I know, it's a crazy Crazy day in a crazy week out there so we.
Where we're honored that you spend time looking at Heska or Super excited about the work we're doing.
We can't grew on a fantastic place us a lot of hard work a lot of things still to be done but.
We're entering the second half of a five year plan and we really like our position I do want to mention one thing housekeeping, we previously announced an analyst Investor day on May 20 at the New York City.
To discuss our strategic growth strategy and our multiyear outlook.
Well the anticipated closing of skill.
Right around the same time and the anticipated first quarter earnings release, so close to that scheduled date, we're going to move that analyst and Investor day to September 16th.
In New York City, a will discuss our growth strategy, our consolidated performance, including all the major acquisitions.
Hey demonstration of our element U.S. product.
And ER and most importantly, a multiyear outlook. So we'll move that the details around that event will be forthcoming.
With that everybody have a great day and again, thank you for taking the time for our call today Bye.
This concludes today's call. Thank you all for your participation you May now go ahead and disconnect.
[noise].